ImmunityBio ISPOR data show why NMIBC treatment choices are becoming harder to standardize
Bladder cancer care is shifting from survival alone to treatment trade-offs. ImmunityBio’s NMIBC survey shows why preference now matters.
ImmunityBio resubmits FDA application for ANKTIVA in bladder cancer after agency requests updated efficacy data
ImmunityBio has resubmitted its supplemental biologics license application to the U.S. Food and Drug Administration for ANKTIVA (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guerin for BCG-unresponsive non-muscle invasive bladder cancer with papillary tumors, after the agency requested updated long-term efficacy data in March 2026. The resubmission follows a regulatory exchange that began in January […]
Can ctDNA-guided bladder preservation become viable after Signatera’s ASCO GU data?
New ASCO GU data shows how Signatera ctDNA may guide bladder preservation and adjuvant therapy decisions in muscle-invasive bladder cancer. Read the analysis.